PURPOSE: The goals of this study were to investigate whether beta-defensins are differentially expressed in the conjunctival epithelium of patients with moderate dry eye when compared with normal subjects and whether proinflammatory cytokines or bacteria can modulate the expression of human beta-defensins (hBDs)-1, -2, and -3 by conjunctival epithelial cells. METHODS: RNA extracted from conjunctival impression cytology specimens of eight normal subjects and nine patients with moderate dry eye was used in RT-PCR to detect mRNA for hBDs-1, -2, and -3. Two conjunctival epithelial cell lines and primary cultured conjunctival epithelial cells were treated with proinflammatory cytokines or heat-killed Pseudomonas aeruginosa. RT-PCR and immunoblot analysis were used to detect mRNA for hBD-1, -2, and -3 and protein secretion of hBD-2, respectively. RESULTS: hBD-2 message was detected in RNA samples of eight of nine patients with dry eye, but not in any of the normal subjects' samples, whereas hBD-1 and -3 were detected in all subjects tested. RT-PCR revealed an upregulation of hBD-2 but no difference in expression of hBD-1 and -3 in cultured conjunctival cells after a 24-hour treatment with 10 ng/mL interleukin (IL)-1beta, IL-1beta and tumor necrosis factor-alpha (10 ng/mL) or heat-killed Pseudomonas aeruginosa (1 million colony-forming units; n = 3). hBD-2 expression was upregulated from 4 hours of treatment with IL-1beta (at 10 ng/mL; (n = 2-3) and at a concentration of 0.1 ng/mL IL-1beta (24-hour treatment; n = 2-3). Immunoblots demonstrated protein secretion results corresponding to the RT-PCR data. CONCLUSIONS: hBD-2 was expressed only in the conjunctival epithelium of patients with moderate dry eye. Because cytokines such as IL-1beta and TNF-alpha induced the expression of hBD-2 by conjunctival epithelial cells and because increased proinflammatory cytokine activity is a feature of dry eye disease, it can be speculated that the hBD-2 upregulation observed in subjects with moderate dry eye is mediated by proinflammatory cytokine activity.
PURPOSE: The goals of this study were to investigate whether beta-defensins are differentially expressed in the conjunctival epithelium of patients with moderate dry eye when compared with normal subjects and whether proinflammatory cytokines or bacteria can modulate the expression of humanbeta-defensins (hBDs)-1, -2, and -3 by conjunctival epithelial cells. METHODS: RNA extracted from conjunctival impression cytology specimens of eight normal subjects and nine patients with moderate dry eye was used in RT-PCR to detect mRNA for hBDs-1, -2, and -3. Two conjunctival epithelial cell lines and primary cultured conjunctival epithelial cells were treated with proinflammatory cytokines or heat-killed Pseudomonas aeruginosa. RT-PCR and immunoblot analysis were used to detect mRNA for hBD-1, -2, and -3 and protein secretion of hBD-2, respectively. RESULTS:hBD-2 message was detected in RNA samples of eight of nine patients with dry eye, but not in any of the normal subjects' samples, whereas hBD-1 and -3 were detected in all subjects tested. RT-PCR revealed an upregulation of hBD-2 but no difference in expression of hBD-1 and -3 in cultured conjunctival cells after a 24-hour treatment with 10 ng/mL interleukin (IL)-1beta, IL-1beta and tumor necrosis factor-alpha (10 ng/mL) or heat-killed Pseudomonas aeruginosa (1 million colony-forming units; n = 3). hBD-2 expression was upregulated from 4 hours of treatment with IL-1beta (at 10 ng/mL; (n = 2-3) and at a concentration of 0.1 ng/mL IL-1beta (24-hour treatment; n = 2-3). Immunoblots demonstrated protein secretion results corresponding to the RT-PCR data. CONCLUSIONS:hBD-2 was expressed only in the conjunctival epithelium of patients with moderate dry eye. Because cytokines such as IL-1beta and TNF-alpha induced the expression of hBD-2 by conjunctival epithelial cells and because increased proinflammatory cytokine activity is a feature of dry eye disease, it can be speculated that the hBD-2 upregulation observed in subjects with moderate dry eye is mediated by proinflammatory cytokine activity.
Authors: C Vitali; S Bombardieri; H M Moutsopoulos; J Coll; R Gerli; P Y Hatron; L Kater; Y T Konttinen; R Manthorpe; O Meyer; M Mosca; P Ostuni; R A Pellerito; Y Pennec; S R Porter; A Richards; B Sauvezie; M Schiødt; M Sciuto; Y Shoenfeld; F N Skopouli; J S Smolen; F Soromenho; M Tishler; M J Wattiaux Journal: Ann Rheum Dis Date: 1996-02 Impact factor: 19.103
Authors: O Chertov; D F Michiel; L Xu; J M Wang; K Tani; W J Murphy; D L Longo; D D Taub; J J Oppenheim Journal: J Biol Chem Date: 1996-02-09 Impact factor: 5.157
Authors: R L Terry; C M Schnider; B A Holden; R Cornish; T Grant; D Sweeney; D La Hood; A Back Journal: Optom Vis Sci Date: 1993-03 Impact factor: 1.973
Authors: S Rodríguez-Martínez; M E Cancino-Díaz; L Jiménez-Zamudio; E García-Latorre; J C Cancino-Díaz Journal: Br J Ophthalmol Date: 2005-07 Impact factor: 4.638
Authors: Rodrigo Guimaraes de Souza; Zhiyuan Yu; Michael E Stern; Stephen C Pflugfelder; Cintia S de Paiva Journal: J Ocul Pharmacol Ther Date: 2018-06-29 Impact factor: 2.671
Authors: Fabian Garreis; Thomas Schlorf; Dieter Worlitzsch; Philipp Steven; Lars Bräuer; Kristin Jäger; Friedrich P Paulsen Journal: Histochem Cell Biol Date: 2010-06-05 Impact factor: 4.304
Authors: Srihari Narayanan; Rachel L Redfern; William L Miller; Kelly K Nichols; Alison M McDermott Journal: Ocul Surf Date: 2013-01-29 Impact factor: 5.033
Authors: J Viiri; H M Jauhonen; A Kauppinen; T Ryhänen; T Paimela; J Hyttinen; I Sorri; J K Laihia; L Leino; K Kaarniranta Journal: Mol Vis Date: 2009-09-08 Impact factor: 2.367